Umoja Biopharma to Showcase Research at ACR Convergence 2024
Umoja Biopharma, Inc., an innovative player in the field of immunotherapy, is gearing up to present a significant development at the upcoming American College of Rheumatology (ACR) Convergence 2024. This prestigious event, set to occur mid-November, will host numerous leading minds in rheumatology, offering a platform for knowledge exchange, groundbreaking research, and advancements in treatment methodologies.
Innovative Approach to CAR-T Therapies
Umoja is focused on generating off-the-shelf treatments that significantly enhance the effectiveness of CAR-T cell therapies, particularly in the realms of oncology and autoimmune diseases. The company is excited to present findings on its cutting-edge VivoVec™ in vivo gene delivery technology at the conference. This technology is poised to be a game-changer in how autoimmune diseases are treated, harnessing the body’s own immune resources to combat ailments more efficiently.
Details of the Presentation
The oral presentation is titled "In Vivo Generation of B Cell Depleting CAR T Cell Therapies for Treatment of Autoimmune Diseases". It will be held during the session focused on Miscellaneous Rheumatic & Inflammatory Diseases II, specifically on Tuesday, November 19, at 11:00 a.m. ET. Maura Parker, Ph.D., Principal Scientist in In Vivo Sciences at Umoja, will lead this session. Enthusiasts and professionals in the medical community can look forward to detailed insights and discussions surrounding the implications of these new therapies.
The Science Behind VivoVec™ Technology
Umoja's proprietary VivoVec™ technology represents a pioneering milestone in the biopharmaceutical arena. This platform is designed to effectively empower the patient’s immune system, inspiring it to engage and fight against diseases. The collaborative efforts of scientists and researchers behind VivoVec™ reflect a commitment to improving patient outcomes in ways that were once thought to be unattainable.
Commitment to Patient Accessibility
Umoja Biopharma believes fervently that innovation should translate directly into improved patient access and outcomes. Their strategic operations, including a top-tier lentiviral vector development facility located in Louisville, Colorado, underline the company's goals. By fostering advancements in CAR-T cell therapies, Umoja opens the door for broader access to these life-saving treatments, enabling a new era of healthcare where more patients enjoy enhanced quality of life.
Connecting with the Community
Beyond its groundbreaking research, Umoja the importance of building relationships within both the medical and investor communities. Potential investors, stakeholders, and media representatives can direct their inquiries to dedicated contacts within the company. Stephen Jasper from Gilmartin Group and Matt Wright from Real Chemistry are available to facilitate communications surrounding the upcoming presentation and the future direction of Umoja Biopharma.
Frequently Asked Questions
What is the purpose of Umoja Biopharma’s presentation at ACR Convergence 2024?
Umoja Biopharma aims to showcase their innovative VivoVec™ technology and the development of CAR T cell therapies targeting autoimmune diseases.
Who will be presenting on behalf of Umoja Biopharma?
Maura Parker, Ph.D., the Principal Scientist of In Vivo Sciences at Umoja Biopharma, will be the presenting speaker.
What advancements are being highlighted in the upcoming presentation?
The presentation will focus on in vivo gene delivery technology and the efficacy of B cell depleting CAR T cell therapies for autoimmune conditions.
What is VivoVec™ technology?
VivoVec™ technology is Umoja's proprietary method that enhances the body's own immune response to fight diseases effectively.
How can investors and media connect with Umoja Biopharma?
Investors and media representatives can reach out to Stephen Jasper and Matt Wright for inquiries and further information about the company and its innovations.
